[Diphtheria epidemic in eastern Switzerland in 1974]. 1977

T Wegmann, and K Baerlocher, and O Geel, and U Krech, and E Schmid, and F Flury, and P Krähenmann, and R Thürlimann, and A Wegmann

A diphtheria epidemic in the eastern part of Switzerland in 1974 and the measures which were taken for its management and eradication are described. In particular it is pointed out that at present diphtheria displays atypical clinical symptoms in Europe, a fact that renders the diagnosis very difficult in many cases. Therefore, it is important to perform a throat swab in every patient with suspected diphtheria; it is also necessary to explicitly require a search for C. diphtheriae. The early recognition and early treatment of diphtheria with penicillin or erythromycin is of the utmost importance in order to avoid neurological and cardiac complications. With regard to the management and eradication of a diphtheria epidemic, the most important measures are rapid antibiotic protection of all contacts and a widespread immunization of the population. Vaccination of adults with a DiTe vaccine containing a reduced amount of Di-toxoid is recommanded.

UI MeSH Term Description Entries
D007116 Immunization, Passive Transfer of immunity from immunized to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (ADOPTIVE TRANSFER). Convalescent Plasma Therapy,Immunoglobulin Therapy,Immunotherapy, Passive,Normal Serum Globulin Therapy,Passive Antibody Transfer,Passive Transfer of Immunity,Serotherapy,Passive Immunotherapy,Therapy, Immunoglobulin,Antibody Transfer, Passive,Passive Immunization,Therapy, Convalescent Plasma,Transfer, Passive Antibody
D007223 Infant A child between 1 and 23 months of age. Infants
D010406 Penicillins A group of antibiotics that contain 6-aminopenicillanic acid with a side chain attached to the 6-amino group. The penicillin nucleus is the chief structural requirement for biological activity. The side-chain structure determines many of the antibacterial and pharmacological characteristics. (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1065) Antibiotics, Penicillin,Penicillin,Penicillin Antibiotics
D002353 Carrier State The condition of harboring an infective organism without manifesting symptoms of infection. The organism must be readily transmissible to another susceptible host. Asymptomatic Carrier State,Asymptomatic Infection Carrier,Inapparent Infection Carrier,Presymptomatic Carrier State,Presymptomatic Infection Carrier,Super-spreader Carrier,Superspreader Carrier,Asymptomatic Carrier States,Asymptomatic Infection Carriers,Carrier State, Asymptomatic,Carrier State, Presymptomatic,Carrier States,Carrier, Super-spreader,Carrier, Superspreader,Carriers, Super-spreader,Carriers, Superspreader,Inapparent Infection Carriers,Infection Carrier, Asymptomatic,Infection Carrier, Inapparent,Infection Carrier, Presymptomatic,Presymptomatic Carrier States,Presymptomatic Infection Carriers,Super spreader Carrier,Super-spreader Carriers,Superspreader Carriers
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003353 Corynebacterium diphtheriae A species of gram-positive, asporogenous bacteria in which three cultural types are recognized. These types (gravis, intermedius, and mitis) were originally given in accordance with the clinical severity of the cases from which the different strains were most frequently isolated. This species is the causative agent of DIPHTHERIA.
D004165 Diphtheria A localized infection of mucous membranes or skin caused by toxigenic strains of CORYNEBACTERIUM DIPHTHERIAE. It is characterized by the presence of a pseudomembrane at the site of infection. DIPHTHERIA TOXIN, produced by C. diphtheriae, can cause myocarditis, polyneuritis, and other systemic toxic effects. Corynebacterium diphtheriae Infection,Corynebacterium diphtheriae Infections,Infection, Corynebacterium diphtheriae
D004168 Diphtheria Toxoid The formaldehyde-inactivated toxin of Corynebacterium diphtheriae. It is generally used in mixtures with TETANUS TOXOID and PERTUSSIS VACCINE; (DTP); or with tetanus toxoid alone (DT for pediatric use and Td, which contains 5- to 10-fold less diphtheria toxoid, for other use). Diphtheria toxoid is used for the prevention of diphtheria; DIPHTHERIA ANTITOXIN is for treatment. Diphtheria Vaccine,Toxoid, Diphtheria,Vaccine, Diphtheria
D004196 Disease Outbreaks Sudden increase in the incidence of a disease. The concept includes EPIDEMICS and PANDEMICS. Outbreaks,Infectious Disease Outbreaks,Disease Outbreak,Disease Outbreak, Infectious,Disease Outbreaks, Infectious,Infectious Disease Outbreak,Outbreak, Disease,Outbreak, Infectious Disease,Outbreaks, Disease,Outbreaks, Infectious Disease
D004917 Erythromycin A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. Erycette,Erymax,Erythromycin A,Erythromycin C,Erythromycin Lactate,Erythromycin Phosphate,Ilotycin,T-Stat,Lactate, Erythromycin,Phosphate, Erythromycin,T Stat,TStat

Related Publications

T Wegmann, and K Baerlocher, and O Geel, and U Krech, and E Schmid, and F Flury, and P Krähenmann, and R Thürlimann, and A Wegmann
June 1996, Vaccine & immunization news : the newsletter of the Global Programme for Vaccines and Immunization,
T Wegmann, and K Baerlocher, and O Geel, and U Krech, and E Schmid, and F Flury, and P Krähenmann, and R Thürlimann, and A Wegmann
September 2015, Therapeutische Umschau. Revue therapeutique,
T Wegmann, and K Baerlocher, and O Geel, and U Krech, and E Schmid, and F Flury, and P Krähenmann, and R Thürlimann, and A Wegmann
January 1999, Emerging infectious diseases,
T Wegmann, and K Baerlocher, and O Geel, and U Krech, and E Schmid, and F Flury, and P Krähenmann, and R Thürlimann, and A Wegmann
August 1996, Lancet (London, England),
T Wegmann, and K Baerlocher, and O Geel, and U Krech, and E Schmid, and F Flury, and P Krähenmann, and R Thürlimann, and A Wegmann
April 1915, California state journal of medicine,
T Wegmann, and K Baerlocher, and O Geel, and U Krech, and E Schmid, and F Flury, and P Krähenmann, and R Thürlimann, and A Wegmann
June 1977, Canadian Medical Association journal,
T Wegmann, and K Baerlocher, and O Geel, and U Krech, and E Schmid, and F Flury, and P Krähenmann, and R Thürlimann, and A Wegmann
January 1994, Archives of virology,
T Wegmann, and K Baerlocher, and O Geel, and U Krech, and E Schmid, and F Flury, and P Krähenmann, and R Thürlimann, and A Wegmann
January 1978, Revista chilena de pediatria,
T Wegmann, and K Baerlocher, and O Geel, and U Krech, and E Schmid, and F Flury, and P Krähenmann, and R Thürlimann, and A Wegmann
August 1941, Canadian Medical Association journal,
T Wegmann, and K Baerlocher, and O Geel, and U Krech, and E Schmid, and F Flury, and P Krähenmann, and R Thürlimann, and A Wegmann
February 1949, American journal of public health and the nation's health,
Copied contents to your clipboard!